Results 161 to 170 of about 3,493,599 (282)

From perception to modelling: Nature-based solutions as a tool for coastal risk management. [PDF]

Camb Prism Coast Futur
d'Avdeew M, Janin L, Goeldner-Gianella L, Sigwald R, Levasseur A, Lecroart J.   +5 more
europepmc   +1 more source

Correction to: Potential of seagrass habitat restorations as nature-based solutions: Practical and scientific implications in Indonesia. [PDF]

Ambio, 2023
Rifai H, Quevedo JMD, Lukman KM, Sondak CFA, Risandi J, Hernawan UE, Uchiyama Y, Ambo-Rappe R, Kohsaka R.   +8 more
europepmc   +1 more source

Nature-based solutions: sustainable? [PDF]

Nature, 2017
openaire   +2 more sources

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Assessing the sensitivity of urban aquatic nature-based solutions to hydroclimate variability using stable water isotopes. [PDF]

Environ Monit Assess
Warter MM, Soulsby C, Vierikko K, Muñoz SM, Gebler D, Sojka M, Carreira VD, Antunes C, Pinho P, Tetzlaff D.   +9 more
europepmc   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Digital fabrication of Hybrid Nature-based Solutions as new opportunity for coastal climate change adaptation. [PDF]

Camb Prism Coast Futur
David CG, Kremer J, Ashwini M, Kloft H, Goseberg N.   +4 more
europepmc   +1 more source

Opportunities for Nature-based Solutions to contribute to Climate-Resilient Development Pathways. [PDF]

Curr Opin Environ Sustain, 2023
Kinol AD, Arango-Quiroga J, Kuhl L.
europepmc   +1 more source

Changes in Immune‐Inflammation Status and Acute Ischemic Stroke Prognosis in Prospective Cohort

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Inflammation is a critical risk factor for poor outcomes in cerebral infarction. Prior studies focused primarily on baseline inflammation status, neglecting dynamic longitudinal changes. We try to investigate the association between immune‐inflammation status alterations and stroke prognosis, and evaluated three systemic biomarkers'
Songfang Chen, Wenting Huang, Yitian Liu, Xuan Chen, Buyu Ke, Qian Shen, Hanyu Cai, Jing Sun, Yan Li, Yungang Cao, Beilei Hu, Keyang Chen   +11 more
wiley   +1 more source

Global synthesis and regional insights for mainstreaming urban nature-based solutions. [PDF]

Proc Natl Acad Sci U S A
McPhearson T, Frantzeskaki N, Ossola A, Diep L, Anderson PML, Blatch T, Collier MJ, Cook EM, Culwick Fatti C, Grabowski ZJ, Grimm NB, Haase D, Herreros-Cantis P, Kavonic J, Lin BB, Lopez Meneses DH, Matsler AM, Moglia M, Morató J, O'Farrell P, Roy P, Singh C, Wang J, Zhou W.   +23 more
europepmc   +1 more source